Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT113 + pembrolizumab versus pembrolizumab first-line trial in HPV16-positive PD-L1-positive recurrent/metastatic HNSCC
2024-512671-12-00Phase 3Authorised
- Sponsor
- BioNTech SE
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) and metastatic head and neck squamous cell carcinoma (mHNSCC) comparing BNT113 + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoints: Treatment-emergent adverse events, Overall survival and 1 more. Planned start Mar 2021; status: authorised.
02
Drugs
BNT113pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)metastatic head and neck squamous cell carcinoma (mHNSCC)
Beyond the preview
Go deeper on 2024-512671-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512671-12-00.